Pharmatech AI

Pharmatech AI is a German company leveraging artificial intelligence to advance pharmaceutical research, with a specific focus on cannabinoid-based therapies, pain relief, and nanomedicine. The company was founded by Ercan Hayvali, who serves as CEO and has a background in economics, AI research, and blockchain solutions.

The core of its technology is the AI Multi-Drug Interaction Predictor (AI-MDIP), a proprietary model that uses Graph Neural Networks to analyze and predict molecular interactions. This platform is powered by data from the company's own research facility in Mecklenburg-Vorpommern, Germany. This 620,000 m² campus includes a 200 m² "MDIP Practical Laboratory Grow" completed in January 2025, which is dedicated to cultivating cannabis under highly controlled conditions for research. This lab generates over 50,000 proprietary data points each cultivation cycle, training the AI-MDIP to identify new therapeutic synergies with greater predictive accuracy.

The business model is centered on monetizing its research and AI platform through pharmaceutical licenses, subscriptions, and a data marketplace. To fund its growth, the company has introduced the PCH token, a utility token built on the ERC20 standard. This token allows holders to participate in governance, access research results, and earn a share of platform revenues through staking. Pharmatech AI aims to bridge the pharmaceutical and crypto industries, and recently secured a $5 million investment from Rollman Management to expand its research center and develop the PCH token.

Keywords: drug discovery, artificial intelligence, cannabinoid research, nanomedicine, pain therapy, molecular interaction, AI platform, utility token, data marketplace, pharmaceutical licensing